Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, will deliver three presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston. The announcements matter to investors and patients alike because they offer the most detailed public look yet at buntanetap, the company's investigational oral therapy for Alzheimer's disease. The presentations come as Annovis approaches a pivotal clinical data readout in early 2027 and begins preparing a New Drug Application.
The conference program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, along with two poster presentations on Nov. 16-17. One poster will be delivered by Chief Scientific Officer Cheng Fang. The presentations will cover buntanetap's mechanism of action, which targets multiple neurotoxic proteins; the design and baseline characteristics of the pivotal Phase 3 study in early Alzheimer's disease; and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. Headquartered in Malvern, Pennsylvania, the company is developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
The significance extends beyond a single conference appearance. Alzheimer's disease remains a condition with limited effective treatment options, and drug candidates that target multiple toxic proteins represent a distinct approach from therapies focused on a single pathway. If the Phase 3 data, expected in early 2027, support buntanetap's efficacy and safety, the program could move toward regulatory review. For investors, the CTAD presentations provide an opportunity to assess the scientific rationale and trial design before that readout. For patients and caregivers, they signal that a late-stage oral candidate is advancing through clinical development.
Annovis maintains an online presence and provides company updates through its LinkedIn and X channels, and additional details are available through its newsroom. The full press release can be viewed at https://nnw.fm/2k4SQ. The announcement was distributed through NetworkNewsWire, a communications platform that is part of the Dynamic Brand Portfolio at IBN and reaches audiences through InvestorWire and editorial syndication to 5,000+ outlets.
